Tirzepatide is the first approved dual incretin agonist — and the cardiometabolic trial record is large, consistent, and worth reading carefully.

The short version

Tirzepatide is a prescription drug approved by the FDA — first for type 2 diabetes in May 2022, then for chronic weight management in November 2023, and later for obstructive sleep apnea in adults with obesity. It works by activating two gut-hormone receptors at once: the GIP receptor and the GLP-1 receptor (two hormones your body releases after you eat to trigger insulin). No other approved drug does both. In the largest obesity trial to date — SURMOUNT-1 with 2,539 participants — people taking the highest studied dose lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo. In type 2 diabetes trials it reduced HbA1c (a long-term blood sugar marker) by more than any single other agent in head-to-head comparison. It is injected once a week under the skin. The most common side effects are nausea, vomiting, and other gastrointestinal symptoms, especially during dose increases. This site is a reading room for that evidence — what the trials actually measured, and what to watch for. It does not sell anything.

What the Tirzepatide trials measured

Tirzepatide arrived from a simple hypothesis: if two incretin hormones drive the body's meal-time insulin response, a single molecule that activates both receptors should outperform one that activates only the GLP-1 receptor. The discovery paper confirmed it in preclinical models — tirzepatide (then LY3298176) produced greater weight reduction and food intake suppression than a selective GLP-1 agonist in mice ^[1]. A Phase 1 programme in 142 human subjects supported once-weekly dosing and showed reduced fasting glucose versus placebo ^[1].

The clinical development then split into two large parallel programmes. SURPASS tested tirzepatide in type 2 diabetes across five major trials. SURMOUNT tested it in obesity and overweight. The aggregate human evidence base now covers tens of thousands of participants across multiple approved indications and extension studies.

The headline findings from those programmes form the evidence base this site documents. Tirzepatide research on this site covers them in full, including the cardiovascular outcomes data and the kidney substudy. Tirzepatide effects covers what people report, including the downsides.

The cardiometabolic outcomes: what was measured

SURPASS-2, a 40-week phase 3 trial in 1,879 adults with type 2 diabetes, compared tirzepatide against semaglutide 1 mg directly. At the highest dose studied (15 mg), tirzepatide reduced HbA1c by 2.30 percentage points versus 1.86 with semaglutide — a statistically superior result at all three doses tested. Body weight fell by an additional 5.5 kg more with tirzepatide at 15 mg ^[2].

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus a complication but without type 2 diabetes. Over 72 weeks, tirzepatide at 15 mg produced a mean body-weight reduction of 20.9%, versus 3.1% with placebo ^[3]. In the 2025 head-to-head SURMOUNT-5 trial (n=751), tirzepatide at maximum tolerated dose produced -20.2% weight change versus -13.7% with semaglutide at maximum tolerated dose — a statistically significant superiority result ^[4].

Beyond glycaemia and weight, the programme has expanded into cardiovascular outcomes (SURPASS-CVOT), heart failure with preserved ejection fraction (SUMMIT, 2025), obstructive sleep apnea (SURMOUNT-OSA), metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH), and kidney outcomes (SURPASS-4 substudy). The SURPASS-4 substudy found favourable effects on eGFR and albuminuria versus insulin glargine in type 2 diabetes at high cardiovascular risk ^[5].

The legitimacy question: what this site is for

The domain name carries the intent: a lot of what circulates about tirzepatide is noise — compounded versions of uncertain quality, dosing speculation, promotional framing dressed as research. The trial record is real, large, and accessible. This site's job is to read it clearly.

Timeline: tirzepatide entered the FDA approval record in May 2022 for type 2 diabetes. The obesity approval followed in November 2023. Obstructive sleep apnea in adults with obesity was approved subsequently. The international nonproprietary name is tirzepatide — the INN used throughout this site.

The prescribing information carries one boxed warning: a risk of thyroid C-cell tumours based on rodent data. That signal has not been confirmed in humans, but the label contraindication applies to people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[6].

For what is tirzepatide in the clearest terms — the structure, the mechanism, and the approved indications — the dedicated page is the place to start. For the tirzepatide weight loss trial evidence specifically, that page covers the SURMOUNT programme in detail.

The open questions

Three areas remain genuinely unsettled. First, lean-mass loss: a SURMOUNT-1 DXA substudy found that approximately 25% of the weight lost during treatment was lean mass ^[7]. Whether that lean-mass reduction produces meaningful functional impairment is still being characterized. Second, long-term durability: a SURMOUNT-4 withdrawal study showed significant weight regain after stopping treatment, with concurrent worsening of cardiometabolic markers ^[8][9]. This frames tirzepatide as a chronic rather than short-course therapy. Third, gallbladder and biliary disease: a corrected meta-analysis of nine randomised trials found a significantly increased risk of the composite of gallbladder or biliary disease versus controls — relative risk 1.97 (95% CI 1.14 to 3.42) ^[10]. Pancreatitis risk was monitored but did not reach statistical significance in the same analysis.

These open questions are not arguments against the drug's clinical utility — the trial record is real. They are the parts of the evidence base a careful reader needs to carry alongside the headline outcomes.